Myeloproliferative Neoplasms News

Seattle Genetics discontinued a randomized phase 3 trial designed to evaluate vadastuximab talirine for frontline treatment of elderly patients with acute myeloid leukemia.

Tuya Pal, MD, has been appointed associate director of cancer health disparities at Vanderbilt-Ingram Cancer Center.

This year’s ASCO Annual Meeting, held June 2-6 in Chicago, featured the theme “Making a Difference in Cancer Care With You.”

Ruben A. Mesa, MD, has been named director of UT Health San Antonio Cancer Center.

Women who used oral contraceptives did not demonstrate increased long-term cancer risk, according to results of the Royal College of General Practitioner’s Oral Contraception Study.

CHICAGO — Spleen response with momelotinib appeared noninferior to that of ruxolitinib among treatment-naive patients with myelofibrosis, according to results from the phase 3 Simplify clinical trial presented at ASCO annual meeting.

CHICAGO — Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology.

The FDA denied approval of Coherus BioSciences’ biologics license application for CHS-1701, a proposed biosimilar for pegfilgrastim.

President Donald J. Trump selected Norman E. “Ned” Sharpless, MD, to serve as director of NCI.

Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments targeting specific alterations within a patient’s tumor, regardless of cancer type.